Synaptogenix, INC Form 4 insider transactions

Executive Chairman Joshua Silverman received a grant of 200,000 stock options in TAO Synergies Inc. exercisable at $4.80.

Director Bruce Bernstein was granted 55,000 stock options in TAO Synergies Inc. with an exercise price of $4.80.

Director William S. Singer was granted 35,000 stock options in TAO Synergies Inc. with an exercise price of $4.80.

TAO Synergies Inc. CFO Robert Weinstein was granted 30,000 stock options exercisable at $4.80 per share.

Director Robert Ephron of TAO Synergies Inc. was granted 10,000 stock options with an exercise price of $4.80.

TAO Synergies Inc. director William S. Singer acquired 800 stock options with an exercise price of $5.52, vesting one year after April 7, 2026.

TAO Synergies Inc. Director Robert Ephron has filed a Form 4 with the SEC, reporting the acquisition of stock options.

TAO Synergies Inc. reports the grant of stock options to Director Bruce Bernstein, with vesting contingent on continued service.

TAO Synergies Inc.'s CFO, Robert Weinstein, reported the acquisition of 10,000 restricted stock units, the withholding of 4,000 shares for taxes, and the grant of 7,000 employee stock options.

TAO Synergies Director William S. Singer increased his beneficial ownership through RSU vesting and an employee stock option grant, with some shares withheld for tax liability.

Joshua Silverman, Executive Chairman of TAO Synergies Inc., increased his direct beneficial ownership of common stock and received new stock options.

TAO Synergies Inc. Director Jonathan Schechter received a grant of 10,000 employee stock options with an exercise price of $10.38, effective August 6, 2025.

TAO Synergies Director Robert Ephron reported the immediate vesting of 7,500 restricted stock units and the withholding of 3,000 shares for tax purposes.

TAO Synergies Inc. Director Bruce Bernstein reported the acquisition of 25,000 restricted stock units and 12,000 employee stock options, alongside a tax-related disposition of 10,000 shares.

TAO Synergies Inc. Director Bruce Bernstein reported the acquisition of 24,657 restricted stock units and the disposition of 9,863 shares for tax withholding purposes on June 30, 2025.

TAO Synergies Inc. Director and 10% Owner William S. Singer reported the acquisition of 15,410 restricted stock units and the subsequent disposition of 6,164 shares for tax withholding purposes on June 30, 2025.

TAO Synergies Inc.'s Chief Financial Officer, Robert Weinstein, reported the immediate vesting of 15,410 restricted stock units and the subsequent withholding of 6,164 shares for tax purposes on June 30, 2025.

TAO Synergies Inc. Executive Chairman Joshua Silverman reported an acquisition of restricted stock units and a subsequent disposition of shares for tax purposes.

TAO Synergies Inc. Director Jonathan Schechter reported the acquisition of restricted stock units and subsequent disposition of shares for tax withholding purposes.

TAO Synergies Inc.'s Chief Medical Officer and Director, Alan J. Tuchman, reported the immediate vesting of 4,315 restricted stock units and the subsequent withholding of 1,726 shares for tax purposes on June 30, 2025.

Director William S. Singer acquired stock options for 800 shares of Synaptogenix, Inc. at an exercise price of $2.28, vesting after one year of service.

Director Jonathan Schechter acquired stock options in Synaptogenix, Inc. exercisable after one year of service.

Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options exercisable for 800 shares of common stock.

Director William S. Singer acquired stock options in Synaptogenix, Inc. on April 8, 2024.

Director Joshua Silverman of Synaptogenix, Inc. acquires stock options exercisable after one year of service.

Jonathan Schechter, a director of Synaptogenix, Inc., acquired stock options exercisable for 800 shares of common stock on April 8, 2024.

Bruce Bernstein, a director of Synaptogenix, Inc., acquired stock options on April 8, 2024.